Posted by Site Administrator on January 13, 2013
CAMBRIDGE, Massachusetts, January 10, 2013 — The ALS Therapy Development Institute (ALS TDI) has entered into a new collaboration with to-BBB, a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier, to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
“This partnership brings a new potential tool to [...]
Categories: Research News, Treatments
| 
Tags: Aestus Therapeutics, ALS, ALS community, ALS cure, ALS diagnosis, ALS medical care, ALS research, ALS research funding, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Biogen Idec, Bob Stehlin, Central Nervous System (CNS), G-Technology, liposomal drug delivery system, Lou Gehrig's disease, MDA and RGK Foundation, neurodegenerative disorders, PALS, Pieter Gaillard, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Perrin, to-BBB, UCB, world’s first nonprofit biotech institute
| 
No comments
Posted by Site Administrator on December 10, 2012
The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.
Categories: Clinical Trials, Research News, Technology, Treatments
| Tags: 2012 Nobel Prize in Physiology or Medicine, Aestus Therapeutics, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Biogen Idec, Bob Stehlin, Gladstone Institutes, induced pluripotent stem cells, iPS cells, iPS-based ALS therapy, MDA, PALS, RASCALS Foundation, RGK Foundation, Robert A. Stehlin Campaign for ALS, Shinya Yamanaka, sporadic ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Finkbeiner, Steve Perrin, TDP-43, TDP-43 protein, UCB, University of California, University of California at San Francisco
| No comments
Posted by Site Administrator on May 16, 2012
The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig’s disease).
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, amyotrophic lateral sclerosis, Armin Mader, Lou Gehrig's disease, Motor Neuron Disease, neuromuscular junction, Neurotun, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin
| No comments
Posted by Site Administrator on February 20, 2012
With regard to the development of an efficacious treatment for ALS, we are still in its infancy. There is much more to be done—and much more quickly than we’ve seen.
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, compassionate access, Director of Neurology Clinical Trials Unit, FDA, fingolimod, Gilenya, Lou Gehrig’s disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, off-label, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
Posted by Site Administrator on February 19, 2012
Many patients with Lou Gehrig’s disease, a fatal disorder formally known as amyotrophic lateral sclerosis, may want to try the drug on their own—even though there’s no evidence that it is safe or effective in patients with the disease.
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, Director of Neurology Clinical Trials Unit, fingolimod, Gilenya, Lou Gehrig’s disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
Posted by Site Administrator on February 14, 2012
The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka:fingolimod/Gilenya®) as a potential treatment for ALS (Lou Gehrig’s disease).
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, Director of Neurology Clinical Trials Unit, fingolimod, Gilenya, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
